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Purpose: Using dynamic contrast-enhanced magnetic
resonance imaging (DCE-MRI) in a rat glioma model, and
nested model selection (NMS), to compare estimates of the
pharmacokinetic parameters vp, K
trans, and ve for two dif-
ferent contrast agents (CAs)—gadofosveset, which reversi-
bly binds to human serum albumin, and gadopentetate
dimeglumine, which does not.
Materials and Methods: DCE-MRI studies were per-
formed on nine Fisher 344 rats inoculated intracerebrally
with 9L gliosarcoma cells using both gadofosveset and
gadopentetate. The parameters vp, K
trans, and ve were esti-
mated using NMS.
Results: Ktrans estimates using gadofosveset, compared
to gadopentetate, differed in their means (gadofosveset
0.025 6 0.008 min1 vs. gadopentetate 0.046 6 0.011
min1; P ¼ 0.0039). This difference notwithstanding, the
intraclass correlation coefficient (ICC) for the two esti-
mates of Ktrans showed nearly perfect linear dependence
(ICC ¼ 0.8479 by Pearson’s r). Other estimates, ve (gado-
fosveset 22.7 6 4.7% vs. gadopentetate 23.6 6 5.6%; P ¼
0.4258) and vp (gadofosveset 1.5 6 0.5% vs. gadopente-
tate 1.6 6 0.4%; P ¼ 0.25), were not different in their
means between the two CAs, and there was almost perfect
agreement for ve (ICC ¼ 0.8798) and substantial agree-
ment for vp (ICC ¼ 0.7981) between the two CAs.
Conclusion: Estimates of Ktrans were statistically differ-
ent using gadofosveset and gadopentetate, whereas ve
and vp were similar with two CAs. NMS produced robust
estimates of pharmacokinetic parameters using DCE-MRI
that show promise as important measures of tumor phys-
iology and microenvironment.
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DYNAMIC CONTRAST-ENHANCED T1-weighted mag-
netic resonance imaging (DCE-MRI) is being increas-
ingly used in various clinical trials involving brain
tumors. It allows characterization of the vascular
microenvironment in tumors by measurement of a
range of parameters, such as Ktrans (forward transfer
constant), kep (reverse transfer constant), ve (volume
of the extravascular extracellular space), and vp (blood
plasma volume) (1,2). These parameters reflect spe-
cific physiologic characteristics and hence relate to
various aspects of tumor biology. One of the hurdles
in obtaining these quantitative metrics is a lack of
robust methods for approaching the problem of para-
metric estimation using multicompartmental pharma-
cokinetic models (3). Another issue is that current
Food and Drug Administration (FDA)-approved
extravascular contrast agents (CAs) used for the
assessment of vascular parameters in solid tumors
are relatively small (molecular weight <1 kDa) (4).
Thus, their transfer rates from the vasculature to the
extravascular extracellular space (EES) are often very
high in solid tumors. This generates a need for rapid
sampling of the dynamic behavior of the CA in both
tissue and arterial system, and also raises the possi-
bility that the delivery of CA to tissue may be flow-
limited in portions of very aggressive tumors.
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Intravascular or blood pool CAs are being studied
for many clinical applications. For example, gadofos-
veset has been recently approved by the FDA for MR
angiographic application in aorto-iliac disease (5).
Gadofosveset is a blood pool agent that binds reversi-
bly to serum albumin, distributes primarily in the
intravascular space, exhibiting a prolonged plasma
half-life and increased T1 relaxivity at 1.5 T. Since the
albumin-gadofosveset compound has an effective
molecular weight in excess of 6 kDa, the dynamics of
the bound fraction will therefore be slow compared to
an extravascular agent, making the delivery of larger
CA permeability limited rather than flow-limited.
Experience with intravascular or blood pool MR CAs
in intracranial tumors is limited. One study by
Adzamli et al (6) at 1.5 T demonstrated that small-
molecule, albumin-binding blood pool CAs increased
dose effectiveness and lengthened contrast enhance-
ment in an intracranial mouse glioma model. A study
by Essig et al (7) showed that gadofosveset produced
greater, longer-lasting contrast enhancement com-
pared to conventional agents in a variety of human
brain tumors.
To our knowledge, gadofosveset has not been used
to quantitatively estimate tumor kinetics using a
DCE-MRI nested model selection (NMS) procedure in
rat gliomas. The purpose of our study was to measure
and compare the parameters of vascular physiology
such as vp, K
trans, and ve in a rat model of human gli-
oma using two different kinds of CAs: a primarily
intravascular or blood pool CA (gadofosveset) and an




9L gliosarcoma cells were grown in Dulbecco’s modi-
fied Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum (FBS) in 5% CO2/95% air at 37
C
in a humidified incubator. Cells were harvested and
resuspended at a concentration of 8  107 per mL of
serum-free media; 5 mL of the cell suspension con-
taining 4  105 cells was implanted into the rat
brain.
Rat Brain Tumor Model
This study was carried out in strict accordance with
the recommendations in the Guide for the Care and
Use of Laboratory Animals of the National Institutes
of Health. The protocol was approved by the Institu-
tional Animal Care and Use Committee of Henry Ford
Hospital. Surgery was performed under anesthesia
and all efforts were made to minimize suffering. Nine
Fisher 344 female rats were inoculated intracerebrally
with 9L gliosarcoma cells. Animals were anesthetized
with 100 mg/kg ketamine and 15 mg/kg xylazine
intraperitoneally. The surgical zone was shaved,
swabbed with betadine solution, the eyes coated with
Lacri-lube, and the animal was immobilized in a small
animal stereotactic device (Kopf, Cayunga, CA). A 1-
cm incision was made 2 mm to the right of the mid-
line and 1 mm retro-orbitally. The skull was exposed
with cotton-tip applicators and an HP-4 dental drill
bit was used with a micromanipulator to drill a hole 3
mm to the right of the bregma, taking care not to pen-
etrate the dura. A #2701 10 mL Hamilton syringe with
a #4 point, 26-gauge needle containing tumor cells (4
 105) in 5 mL was lowered to a depth of 3.5 mm,
then raised to a depth of 2.5 mm. The tumor cells
were injected stepwise at a rate of 0.5 mL/min until
the entire volume was injected.
During and after injection, careful note was made of
any reflux from the injection site. After completing the
injection, the syringe was withdrawn in a stepwise
manner. The surgical hole was sealed with bone wax.
Finally, the skull was swabbed with betadine before
suturing the skin over the injection site. Animals that
developed significant symptoms or failed to develop
tumors were sacrificed.
MRI Methods: DCE-MRI
A DCE-MRI was performed in each group of animals.
An appropriate state of anesthesia was obtained with
isoflurane (3% for induction, 0.7% to 1.5% mixed with
O2 for maintenance).
MRI was obtained with a 3T clinical system (Signa
Excite, GE Healthcare, Milwaukee, WI) using a Lutz-
cage small animal radiofrequency (RF) coil of 50 mm
diameter  108 mm RF rung length (Doty Scientific,
Columbia, SC). After positioning using a triplanar
FLASH sequence, MR studies were performed using pre-
and postcontrast-enhanced T1-weighted MRI scans.
The following parameters were used to acquire the
images: T1-weighted multislice sequence (TR/TE ¼
500/12 msec, 256  256 matrix, 13–15 slices, 1 mm
thick, 40  30 mm field of view [FOV], number of excita-
tions [NEX] ¼ 2–4). To generate T1 maps from precon-
trast images, 3D SPGR images with multiple flip angles
2, 4, 8, 12, 15, 20, 25, 30, and 35 were acquired.
The following parameters were used to acquire the 3D
SPGR images; TR ¼ 5.65 msec, TE ¼ 1.35 msec using a
128  128 matrix, FOV ¼ 60  60  18 mm3, and NEX
¼ 1. Effective slice thickness was 1.5 mm. To obtain
dynamic postcontrast 3D-SPGR images for 15 minutes,
a fixed flip angle of 30 was used. Acquisition of SPGR
images started before the administration of contrast
agents to have baseline T1-signals and time interval
between image sets was 11.57 seconds.
MRI Methods: Two Different CAs
Tail veins were catheterized using a 24G needle infu-
sion kit. The intravascular agent gadofosveset (t1/2
elimination phase ¼ 16.3 h) was administered at 0.12
mL/kg (0.03 mmol/kg) over 10 seconds, followed by a
saline flush. The extravascular agent gadopentetate
(t1/2 elimination phase ¼ 1.6 h) was administered at
0.2 mL/kg (0.1 mmol/kg) over 10 seconds, followed
by a saline flush. MRI was obtained as the injection
was administered.
Animals were randomized for the CA used. After
tumor implantation (day 0), a contrast-enhanced MRI
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study was performed on day 13 using either gadofos-
veset or gadopentetate. On day 14, the remaining CA
was used. Of the nine rats, five were scanned with
gadofosveset first, followed by gadopentetate and four
were scanned with gadopentetate first, followed by
gadofosveset.
MRI Methods: DCE-MRI NMS
NMS was performed using our previously described
methods (8). First, T1 maps were created using the
multiflip angle (2 to 35) fast SPGR 3D images to
establish the baseline precontrast T1 values on a
voxel-by-voxel basis. Then DR1 concentration–time
maps were created using the baseline T1 maps, 3D
SPGR dynamic sequences, and the ratio of postcon-
trast to precontrast signal for each voxel. This repre-
sented the change in contrast concentration in the
tissues over time. A previously reported (9) standard
radiological arterial input function (SRAIF) was time-
shifted according to the baseline of a manually
selected profile of CA concentration in blood (main
vessels) from the DR1 maps. This allowed us to gener-
ate an SRAIF which was temporally matched with the
Figure 1. A: Representative post-
contrast T1 image of an animal brain
tumor. B: Example of ROIs drawn for the
whole lesion and the central core. C–H:
Representative parametric maps for
each of the vascular parameters using
gadofosveset and gadopentetate. C:
Ktrans map using gadofosveset. D: Ktrans
map using gadopentetate. E: ve map
using gadofosveset. F: ve map using
gadopentetate. G: vp map using gadofos-
veset. H: vp map using gadopentetate.
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profile of the CA concentration in blood for major ves-
sels in DR1 maps. Next, a region of interest (ROI) was
manually selected in the white matter area (which
was assumed to have about 1% of plasma volume)
(10). Then the average time trace of CA concentration
in this area was calculated and the area under this
curve was used to normalize the adjusted SRAIF. It is
notable that this SRAIF was used as an input function
for both contrast agents, and was at best an approxi-
mation for the unbound fraction of the gadofosveset.
Using SRAIF, the concentration–time data in each
voxel was fitted to one of the four different nested
models, which was best supported by the data. Model
0 represents no contrast filling, model 1 represents
contrast filling of normal brain microvasculature with-
out leakage, model 2 represents contrast leakage in
abnormal microvasculature without reabsorption, and
model 3 represents contrast leakage with reabsorp-
tion. The nested models were used to calculate the
forward transfer constant Ktrans, extracellular extrava-
scular volume ve, and plasma volume vp. Further
technical details may be found in our previous report
(8).
MRI Methods: ROI Analysis
ROIs were drawn manually onto the generated maps
of Ktrans, ve, and vp using ImageJ software (NIH,
Bethesda, MD), and the same ROI for each slice was
used for each of the parameters measured. For the
whole tumor, ROIs were drawn around the entire cir-
cumference of the tumor on every section. The mean
values for Ktrans, ve, and vp within each ROI were
recorded and normalized to the total area of ROIs for
all sections containing tumor. For the central core, a
single slice was selected containing the largest area of
tumor, and an ROI was drawn around approximately
the central third of the tumor diameter. The mean
value for Ktrans, ve, and vp was recorded for this ROI.
Examples of MRI images, ROIs, and parametric maps
are shown in Fig. 1.
Statistical Analysis
Descriptive statistics for the measurements of Ktrans,
ve, and vp were computed for the two CAs, for the
whole tumor as well as from the central core of the
tumor. Nonparametric Wilcoxon signed rank tests
were conducted to compare the results from the gado-
fosveset and gadopentetate CAs for both the whole
tumor and the central core of the tumor, separately.
Intraclass correlation coefficients (ICC) were computed
to assess the agreement or reliability between the two
CAs for ve and vp. Landis and Koch (11) used the fol-
lowing cutpoints for interpreting the degree of agree-
ment, which ranges from less than 0 to 1 (<0
representing poor or no agreement, 0.01–0.20 slight
agreement, 0.21–0.40 fair agreement, 0.41–0.60 mod-
erate agreement, 0.61–0.80 substantial agreement,
and 0.81–1.00 almost perfect agreement). In addition,
Bland–Altman plots were done to demonstrate the
amount of agreement/disagreement between the CAs
for each measurement. These plots represent the dif-
ference of the two CAs on the y-axis versus the mean
of the two CAs on the x-axis. Because it was antici-
pated that the Ktrans values would differ for the two
CAs, statistical methods for agreement were not the
appropriate analyses for this measure. Pearson’s cor-
relation coefficients were computed to assess the cor-
relation or association between the two CAs. Landis
and Koch’s cutpoints were also used here for interpre-
tation. Scatterplots with regression lines were also
done to visually inspect the relationships.
RESULTS
For the whole tumor, Ktrans measurements were signif-
icantly lower (P ¼ 0.0039) using gadofosveset (mean ¼
0.025 6 0.008) compared to gadopentetate (mean ¼
0.046 6 0.011). Despite the statistically significant
difference in the mean values, the Pearson’s correla-
tion coefficient indicates that there was almost perfect
correlation between the two CAs (Table 1, Fig. 2). Esti-
mates of both ve (gadofosveset: mean ¼ 22.7 6 4.7,
gadopentetate: mean ¼ 23.6 6 5.6) and vp (gadofosve-
set: mean ¼ 1.5 6 0.5, gadopentetate: mean ¼ 1.6 6
0.4) as a percentage were not statistically different
between the two CAs (P ¼ 0.425 and P ¼ 0.25, respec-
tively). Almost perfect agreement between the two CAs
was noted for ve, while substantial agreement was
noted for vp (Table 1).
In the Bland–Altman plots for vp, the differences are
scattered and clustered around zero, again showing
Table 1






Ktrans (min1) Gadofosveset 0.879* Almost perfect
Gadopentetate
ve (%) Gadofosveset 0.880
y Almost perfect
Gadopentetate





Figure 2. Scatterplot for Ktrans.
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the almost perfect agreement (Fig. 3). However, for ve
the differences are scattered around zero but appear
to become more widespread for higher values of ve,
indicative of substantial agreement (Fig. 4).
For the central core of the tumor, Ktrans measure-
ments were again significantly lower (P ¼ 0.0039)
using gadofosveset (mean ¼ 0.026 6 0.008) compared
to gadopentetate (mean ¼ 0.045 6 0.010). However,
the correlation indicates that there was only a fair
association between the measurements (Table 2, Fig.
2). No statistically significant differences were
observed between the CAs for ve (gadofosveset: mean
¼ 22.0 6 4.6, gadopentetate: mean ¼ 25.4 6 5.7) and
vp (gadofosveset: mean ¼ 2.2 6 0.5, gadopentetate:
mean ¼ 2.2 6 0.5) (P ¼ 0.25 and P ¼ 0.937, respec-
tively). Moderate agreement was observed for vp, while
ve only showed slight agreement (Table 2).
In the Bland–Altman plots for vp, the moderate
agreement and lack of statistical differences between
the CAs is displayed in the plot by the differences
being scattered and clustered around zero (Fig. 3).
However, for ve the differences are scattered around
zero and appear to become more widespread for
higher values of ve, showing the slight agreement
between the CAs (Fig. 4).
DISCUSSION
In the whole tumor, estimates of vp, a parameter that
is relatively independent of the temporal details of the
input function, did not differ for the two contrast
agents and showed a substantial agreement. Esti-
mates of ve, the fractional volume of the interstitial
space, a parameter that depends on the ratio of the
forward volume transfer constant Ktrans and the
reverse transfer constant kep, did not differ between
the two contrast agents and demonstrated a near-
perfect agreement. Estimates of both Ktrans and kep
are dependent on the comparative dynamics of the
input function and the tissue response function, but
since ve is calculated as the ratio of the two, system-
atic effects due to an error in the input function tend
to cancel.
Estimates of Ktrans, a parameter that, as noted,
depends substantially on a good estimate of the input
function, were highly correlated, but differed between
the two CAs in their mean estimates. For the two con-
trast agents, the estimates for the volume fractions vp
and ve are well within the range of estimates using
other techniques in similar tumors (12), and the esti-
mate for Ktrans of gadopentetate in the current study
is on the same order of magnitude as that of Ktrans for
gadopentetate in a U251 glioblastoma model of cere-
bral tumor (13). Contrariwise, the estimate of Ktrans
for gadofosveset is an order of magnitude smaller
than that of an irreversibly bound Gd-albumin com-
pound (14), but on the same order of magnitude as
the estimate for gadopentetate. Significantly, despite
gadofosveset’s binding to albumin, and presumably
also to external protein sites, most of the model 3
region for gadopentetate, in which measurable reverse
transfer of contrast took place, was also a model 3
region for gadofosveset (see Fig. 1E,F, where the non-
zero values of ve mark the extent of the model 3
region). This comparison between the two contrast
agents raises the likelihood that it is mainly the
unbound fraction of gadofosveset that was leaking
from the microvasculature of the tumor. It might be
supposed that, since gadopentetate and the unbound
fraction of gadofosveset have nearly the same molecu-
lar weight, they will have very similar pharmacoki-
netics in their extravasation from the
microvasculature. Once external to the microvascula-
ture, there might have been some binding to intersti-
tial protein pools, but this binding must have
Figure 3. Bland–Altman plot for vp%.
Figure 4. Bland–Altman plot for ve%.
Table 2






Ktrans (min1) Gadofosveset 0.411* Fair
Gadopentetate
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saturated fairly quickly in order for significant reverse
flux to have occurred. The fact that the estimate of
the ratio of Ktrans/kep for the two contrast agents is
nearly identical supports the hypothesis that the two
contrast agents exhibit very similar pharmacokinetics,
but that the input function of gadofosveset may not
be as not well known as that for gadopentetate.
With the foregoing in mind, it appears that, in
assessing the absolute value of Ktrans for the unbound
fraction of gadofosveset, the main problem is that the
input function of the unbound fraction is not well
known and cannot be determined from an MRI study
alone. This is because, even at 3T the longitudinal
relaxivities for the bound and unbound fractions differ
by a factor of 2, but the only judge of arterial and/or
tissue concentration that was available was the change
in R1. The bound fraction is concentration-dependent
(14), varying from around 40% at high concentrations
to 90% at low concentrations. Thus, it can be expected
that the first-pass concentration of the unbound frac-
tion is higher than the equilibrium fraction. The bound
fraction is also species-dependent, with fractional
binding in rat species lying closer to 70% than to 90%
(15). This makes for a very complex kinetic picture in
the input function, and even a somewhat complex
model for the exchange kinetics of the unbound frac-
tion, ignoring to first order the exchange kinetics of the
bound fraction. One ameliorating element in this prob-
lem is that the time constants (Ktrans and kep) of even
the unbound fraction are on the order of tens of
minutes. Since the basic equation of the transfer is that
of a low-pass filter, it is probable that those time con-
stants of the input function that are considerably
shorter than tens of minutes do not strongly influence
the response of the system, and thus do not strongly
influence the parametric estimates of the model.
Since the ratio Ktrans/kep, ie, the parameter ve, agreed
substantially between gadofosveset, which binds to
proteins, and gadopentetate dimeglumine, we have
noted that the transvascular pharmacokinetics of the
two similarly sized CAs were probably similar. There is
some complexity in this inference, since it is unknown
whether the bound/unbound fractions in the intersti-
tium were substantially the same as that in the plasma.
If they were, then the contrast generated from the frac-
tion in the interstitium would have the same relation to
the concentration of CA (ie, the same longitudinal
relaxivity) in the interstitium as it did in the plasma.
Otherwise, the differential relaxivities of the unbound
and bound fractions would generate a different rela-
tionship between CA concentration and contrast.
Noninvasive and accurate estimation of the volume
of the EES (ve) is another potentially important
parameter of tumor microenvironment, which has not
gained enough clinical attention and can be measured
with dynamic studies. It is related to Ktrans and kep or
kb (1,16). Increase of EES is known to occur in brain
tumors and may further lead to evolution of patho-
logic tissue composition, such as increased intercapil-
lary and perfusion distances, and formation of
hypoxia (17). Transport of a molecule in the EES is
dependent on the physiological properties such as
interstitial pressure, but also on the physiochemical
properties (such as size, charge, structure, composi-
tion) of both the EES and the molecule (eg, CA) used
(18). ve estimates in human gliomas range from 20–
40% based on the older literature (19) to more recent
estimates ranging from 43.8–61.1% using 76Br-Bro-
mide and positron emission tomography (PET) exami-
nation (17). Hence, we decided to estimate ve by using
two different CAs and DCE-MRI NMS and demon-
strated almost perfect agreement when using two dif-
ferent CAs for the whole tumor. However, ve estimates
in the central core of the tumor were in poor agree-
ment with the two different CAs, even though they
were within the physiological range. This could be due
to the fact that transport of low molecular weight mol-
ecules is diffusion dominated, and the transport of
the gadofosveset by that modality is probably hin-
dered by its tendency to adhere to interstitial proteins.
This could be particularly important in the central
core of the tumor, as most of the leaky vasculature is
at the periphery of the tumor away from the central
core (20–22). Hence, it is perhaps not surprising that
in the central portion of the tumor, where delivery of
the CA is more likely to be perfusion-limited, esti-
mates of vascular parameters differ for the two CAs.
This insight should be tempered by the uncertainties
concerning the interstitial binding of gadofosveset. The
sources of uncertainty include the different intervoxel
diffusion rates for the two CAs, location-dependent
interstitial binding potentials for gadofosveset, and
possibly location-dependent relaxivities (depending on
the binding potential and bound/unbound fractions)
for gadofosveset. Thus, it would be difficult to state
with certainty the reason for the lack of agreement in
the estimates of pharmacokinetic parameters for the
two contrast agents in the central region of the tumor.
In conclusion, both volume of extravascular extrac-
ellular space and blood plasma can be measured
accurately whether we use currently FDA-approved
extravascular CAs or experimental blood pool CAs in
preclinical cancer models. Ktrans measurements were
significantly lower using a blood pool CA due to the
much larger size of the albumin-bound CA, but even
these were measured accurately using NMS in DCE-
MRI. We demonstrated the stability of NMS in DCE-
MRI for measurement of these important vascular
physiology markers which can provide important
information about the tumor microenvironment and,
hence, could potentially expand their role into clinical
studies as prognostic and/or predictive imaging
biomarkers.
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